Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 3/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133744 | 0.87 | XDH (0.39) | GDAFGFR1FGFR2FGFR3XDH | |
| SCHEMBL9275474 | 0.84 | XDH (0.38) | GDAFGFR1FGFR2FGFR3XDH | |
| SCHEMBL3512356 | 0.80 | GDA (0.35) | GDAFGFR1FGFR2FGFR3XDH | |
| SCHEMBL65614 | 0.74 | GDA (0.40) | GDAFGFR1FGFR2FGFR3XDH | |
| SCHEMBL8591402 | 0.73 | FGFR1 (0.51) | GDAFGFR1FGFR2FGFR3PNP | |
| SCHEMBL16513137 | 0.72 | GDA (0.64) | GDAFGFR1FGFR2FGFR3 | |
| SCHEMBL26155922 | 0.71 | PNP (0.48) | PNPNUDT1 | |
| SCHEMBL6270959 | 0.69 | FYN (0.52) | — | |
| SCHEMBL27503507 | 0.69 | XDH (0.62) | GDAXDH | |
| SCHEMBL4384740 | 0.68 | XDH (0.67) | XDHPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8679454-B2 | Particle immobilized coatings and uses thereof | SURMODICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8158106-B2 | Drug delivery; microparticles immobilized on polymer surface | SURMODICS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090186070-A1 | Particle immobilized coating and uses thereof | Surmodics Coatings, LLC | 2009-07-23 | — | — | US | disclosed |
| EP-1434571-B1 | PARTICLE IMMOBILIZED COATINGS AND USES THEREOF | SURMODICS INC (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1478403-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA, INC. (CA) | 2004-11-24 | — | — | EP | disclosed |
| US-RE38341-E1 | Method for electrokinetic delivery of medicaments | BIOPHORETIC THERAPEUTIC SYSTEMS, LLC | 2003-12-09 | — | — | US | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186070-A1 | Particle immobilized coating and uses thereof | SELP, SELPLG, PLAUR | GDA 2894/4885FGFR1 2010/4885FGFR2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.